Syntimmune's Acquisition

Syntimmune was acquired by Alexion Pharmaceuticals on September 26, 2018.

Syntimmune is a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn).…

Articles about Syntimmune's Acquisition: